Atlas FDA

STA Neoplastine CI Plus (10), (cat. 0667). 12 x 10 ml. in vitro diagnostic for the determination of prothrombin time (PT

FDA device recall Z-0979-2007 · posted 2007-07-03 · Terminated

Recall details

Recalling firm
Diagnostica Stago, Inc.
Reason for recall
Based on the confirmed clotting times in the upper part of the assigned ranges of STA-Coag Control ABN control plasmas when used with STA-Neoplastine CI Plus, use of this lot may cause difficulty during the validation of the STA-Coag Control ABN.
Action taken
Recall notification letters were sent on March 30, 2007 by first class mail. The letter advises customers that lot 061781 of STA-Neoplastine Cl Plus may cause difficulty during the vailidation process of STA-Coag Control ABN control plasmas, and asks that the lot number be discontinued.
Root cause
Other
Status
Terminated
Product code
GJS
Quantity affected
170 units
Distribution
Nationwide.
Date initiated
2007-03-30
Date posted
2007-07-03
Date terminated
2009-11-30
Location
Parsippany, NJ

Monitor recalls programmatically

Recalls and clearances share one API, with change alerts when new recalls post.

Related 510(k) clearances

RecordFirmDate
NEOPLASTINE CI PLUS (K922040)American Bioproducts Co.1992-06-23